Indian J. Applied & Pure Bio. Vol. 40(3), 2046-2049 (2025). **ISSN: 0970-2091**
A web of Science Journal

Transdermal Drug Delivery System: An Overview

Shailendra Patidar, Ashish Gupta*, Ravi Sharma and Gajanan Darwhekar

Acropolis Institute of Pharmaceutical Education and Research,
Indore - 453770 (India)
*Corresponding Email ID: ashish.pharma87@gmail.com

Abstract

Transdermal Drug Delivery Systems (TDDS) offer a non-invasive, patient-friendly route of drug administration with numerous advantages such as bypassing first-pass metabolism and maintaining controlled drug levels in systemic circulation. This review explores the anatomical and physiological aspects of the skin, pathways and mechanisms of drug permeation, formulation strategies, permeation enhancers, types of TDDS, recent advances, applications, and limitations. Emphasis is placed on novel drug delivery systems like microneedles, nanoformulations, and stimuli-responsive patches. The paper concludes with a future outlook and recommendations for improved clinical adoption.

Key words : Transdermal systems, Drug Delivery system, Chemical enhancers, Nanocarriers.

Transdermal drug delivery has emerged as a significant innovation in the pharmaceutical industry due to its potential for improving therapeutic efficacy and patient compliance. It allows drugs to penetrate through the skin directly into systemic circulation, thus avoiding gastrointestinal degradation and hepatic first-pass metabolism[11]. Additionally, TDDS provides a controlled release of drugs, which reduces dosing frequency and side effects[5].

Skin anatomy and permeation pathways :

The skin comprises three main layers: the epidermis, dermis, and hypodermis. The outermost layer, the **stratum corneum**, acts as a major barrier to drug penetration[4]. Drugs can cross the skin via three primary pathways:

- Intercellular (between corneocytes),
- Transcellular (through cells),
- Appendageal (via hair follicles and sweat glands)[14].

Criteria for ideal transdermal drugs :

To be effectively delivered transdermally, a drug should meet specific criteria:

- Molecular weight < 500 Da,
- Log P between 1 and 3 (moderate lipophilicity),

- Low daily dose (<10 mg),
- High potency and low melting point[1,9].

Generations of Transdermal systems :

TDDS have evolved over the years:

- **First-generation systems** include basic patches like nitroglycerin and nicotine, designed for small, lipophilic drugs[3].
- **Second-generation systems** incorporate permeation enhancers such as iontophoresis and chemical enhancers[8].
- **Third-generation systems** use technologies like microneedles, electroporation, and thermal ablation for large molecule delivery[11].

Permeation enhancement strategies :

Chemical and physical methods have been employed to improve drug permeation through the skin barrier:

- **Chemical Enhancers:** Alcohols (*e.g.*, ethanol), DMSO, surfactants, and fatty acids alter the lipid structure of stratum corneum[14].
- **Physical Methods :** Include iontophoresis (low electric current), sonophoresis (ultrasound), microneedles, and electroporation[11].

Types of TDDS :

There are several structural types of TDDS:

- **Matrix Systems :** Drug is embedded in a polymer matrix.
- **Reservoir Systems :** Drug is in a gel or liquid compartment, separated from the skin by a membrane.
- **Adhesive Dispersion Systems:** Drug is dispersed in an adhesive layer[6].
- **Micro-reservoir Systems :** Combine the advantages of matrix and reservoir systems.

Novel and Advanced TDDS :

Innovations in TDDS aim to improve efficacy and drug loading:

- **Microneedles:** Facilitate drug transport through microchannels without pain.
- **Nanocarriers:** Liposomes, niosomes, and ethosomes improve drug solubility and skin penetration[10].
- **Stimuli-responsive systems:** Deliver drugs based on triggers such as temperature, pH, or glucose[13].

Applications :

TDDS are used in various therapeutic areas:

- **Pain management:** Fentanyl patches.
- **Hormone therapy:**Estradiol and testosterone patches.
- **Cardiovascular disorders:**Nitroglycerin patches.
- **Smoking cessation:** Nicotine patches[4,9].

Advantages :

- Avoids first-pass metabolism,
- Sustained and controlled release,
- Improved patient compliance[5].

Disadvantages :

- Limited to potent drugs,
- Risk of skin irritation and sensitivity,
- Slow onset of action[1].

Future perspectives :

Future TDDS developments include:

- **Smart patches** with sensors for glucose or drug-level monitoring,
- **3D-printed transdermal devices** for personalized medicine,
- **AI-integrated systems** for dose titration[11,13].

Clinical case studies of TDDS :

Numerous clinical case studies highlight the success of transdermal systems in various therapeutic areas.

- **Nicotine TDDS:** Clinical studies show that nicotine patches significantly improve smoking cessation rates when combined with behavioral therapy[13].
- **Fentanyl Patches**: Effective in chronic cancer pain management with stable plasma levels and fewer gastrointestinal side effects compared to oral opioids[9].
- **Hormone Replacement Therapy (HRT):** Estradiol patches maintain hormone levels without hepatic first-pass effect, reducing clotting risk compared to oral estrogen[14].

Regulatory and Quality aspects of TDDS:

TDDS must meet strict regulatory standards for safety, efficacy, and quality control.

- **FDA Guidelines:** Require pharmacokinetic bioequivalence, in vitro skin permeation testing, and adhesive performance testing.
- **ICH Q8-Q10 Framework**: Quality by Design (QbD) principles guide the manufacturing and scale-up of TDDS[1].

Key parameters include:

- Drug content uniformity,
- Patch adhesion and flexibility,
- Skin irritation testing[3].

Commercially available TDDS products :

Several products have reached the market with demonstrated therapeutic success.

Product	Active Ingredient	Indication
Nicoderm®	Nicotine	Smoking cessation
Duragesic®	Fentanyl	Chronic pain
Estraderm®	Estradiol	Menopausal symptoms
Catapres-TTS®	Clonidine	Hypertension
Exelon Patch®	Rivastigmine	Alzheimer's Disease[11]

Challenges in TDDS development :

Despite the advantages, certain challenges hinder the widespread adoption of TDDS:

- **Skin variability :** Differences in age, race, hydration, and site of application affect absorption[5].
- **Limited drug types :** Only potent drugs with specific physicochemical profiles are suitable.
- **Risk of allergic dermatitis :** Repeated application can lead to contact allergies or irritation[4].
- **Manufacturing challenges :** Ensuring batch-to-batch consistency in drug content and adhesive properties[8].

Recent innovations and patents in TDDS :

Cutting-edge technologies are transforming TDDS:

- **Microfabricated microneedle arrays :** Enable pain-free delivery of vaccines and peptides[11].
- **Wearable biosensors :** Monitor physiological conditions and adjust drug release in real time.

- **Hydrogel-based patches :** Respond to environmental triggers like pH and temperature[10].

Role of Polymers in TDDS :

Polymers form the backbone of TDDS and influence drug release, adhesion, and skin compatibility.

- **Hydrophilic Polymers :** HPMC, PVP – used in matrix systems.
- **Hydrophobic Polymers :** Ethyl cellulose, Eudragit – offer sustained release.
- **Adhesives :** Polyacrylates provide good skin adhesion and drug dispersion[1].

Polymer-drug interactions also affect drug diffusion and stability in the patch system[12].

Skin models for TDDS testing :

In vitro and in vivo testing is crucial for evaluating TDDS efficacy.

- **Franz Diffusion Cell :** Most commonly used for in vitro skin permeation studies.
- **Animal Models :** Rats, pigs, and monkeys serve as in vivo models due to similar skin properties[4].
- **Artificial Skin Models :** Reconstructed human epidermis offers ethical and reproducible alternatives[9].

References :

1. Benson, H. A. E. (2005). *Current Drug Delivery*, *2:* 23–33.
2. Blasig, J., A. Herz, K. Reinhold, and S. Zieglgansberger, (1973). *Psychopharmacologica* (Berlin), *33:* 19–38.
3. Cleary, G.W. (1993). Transdermal delivery systems: A medical rationale. In *Transdermal Controlled Systemic Medications* (pp. 1–25). Marcel Dekker.
4. Guy, R. H. (2010). Transdermal drug delivery. In: *Drug Delivery* (pp. 399–410). Springer.
5. Hadgraft, J. (2001). *International Journal of Pharmaceutics*, *224:* 1–18.
6. Jain, A. K., P. S. Naruka, and A. Jain, (2008). *Pharmaceutical Reviews*, *6:* 1–10.
7. Johansen, D. A. (1940). *Plant Microtechnique*, pp. 30–35. McGraw Hill, New York.
8. Karande, P., and S. Mitragotri, (2009). *Biochimica et Biophysica Acta*, *1788:* 2362–2373.
9. Kaur, I. P., D. Aggarwal, H. Singh, and S. Kakkar, (2014). *Indian Journal of Pharmaceutical Sciences*, *76*(6): 597–609.
10. Kumar, R., and A. Philip, (2007). *Tropical Journal of Pharmaceutical Research*, *6:* 633–644.
11. Prausnitz, M. R., and R. Langer, (2008). *Nature Biotechnology*, *26:* 1261–1268.
12. Sharma, G. P., N. K. Jain, and B. D. Garg, (1979). *Plana Medica*, *36:* 185.
13. Smith, E. W., and H. I. Maibach, (2006). *Percutaneous Penetration Enhancers*. CRC Press.
14. Williams, A. C., and B. W. Barry, (2004). *Advanced Drug Delivery Reviews*, *56:* 603–618.